ACSM Cancer Exercise Trainer (CET) Practice Test 2025 – Your Comprehensive Guide to Exam Success!

The correct answer identifies doxorubicin, taxanes, and trastuzumab as chemotherapy agents known to have cardiotoxic effects.

Doxorubicin is particularly noted for its ability to cause damage to heart muscle tissue, leading to potential heart failure and other cardiovascular issues. This is because doxorubicin generates free radicals that can impair cardiac myocytes. Taxanes, such as paclitaxel and docetaxel, can also contribute to heart problems, though their effects are less prominent compared to doxorubicin. Trastuzumab, a targeted therapy used primarily in HER2-positive breast cancer, can lead to reduced cardiac function, especially in patients who are also receiving anthracyclines like doxorubicin.

These agents are crucial to consider when implementing exercise interventions for cancer patients, as heart health needs to be closely monitored during treatment due to the risks of cardiotoxicity. Understanding these risks enables cancer exercise trainers to tailor safe and effective exercise programs that support overall health and well-being while considering the potential cardiovascular impacts of these treatments.